COVID-19 is thought to lead to depression by causing inflammation, the body's natural response to injury and infection, in the brain. We have developed a brain scan to detect inflammation and we have used it to study many different illnesses. In this study, we plan to use this scan to look at brain inflammation in those experiencing depression after contracting COVID-19. We hope that results from this study will lead to new treatments specifically for depression caused by inflammation.
Eligibility Criteria
- Age 18 - 75 years of age
- Individuals with post COVID-19, new onset depression symptoms (e.g., low mood, loss of interest, fatigue, brain fog...)
- Individuals that are not currently taking antidepressants or antipsychotics
- Individuals without other psychiatric, neurological, or addiction conditions
- Individuals without blood or coagulation disorders
- Individuals that are not claustrophobic
- Gender: All
- Ethnicity: All
What does the study involve?
- Number of contacts: 1-3 in-person visits
- Compensation offered? Yes
Investigator(s): Dr. Jeff Meyer
Full Study Title: Synaptic Imaging in Major Depressive Episodes After COVID-19
Contact Information:
E-mail: yuhan.liu@camh.ca
REB number: 201-2022
REB Approval Expiry Date: July 31, 2026
PLEASE NOTE:
- Research staff cannot give medical advice over the phone or via email.
- If you have specific questions regarding your health care, please contact your family physician.
- We regret that not everyone screened for a study will be eligible to participate
- For more information about other treatment options for mental illness or addiction offered by CAMH, visit www.camh.ca or call 416-535-8501.